16 results about "Ventricular function" patented technology

The invention relates to the field of medical image examination, and discloses a one-stop heart magnetic resonance examination technology which comprises the following steps: S1, high-integration-degree nuclear magnetic resonance scanning technology: acquiring original data of various heart magnetic resonance examinations through one-time scanning by adopting a high-integration-degree imaging sequence, the original data comprises images with different contrast ratios for measuring myocardial tissues T1, T2 and T2 * and film images for evaluating heart and ventricular functions; s2, expansion type deep learning reconstruction: reconstructing all different T1, T2 and T2 * weighted images and movie images in quantitative imaging and movie imaging data by adopting a reconstruction technology based on deep learning; and S3, quantitative image reconstruction: adopting a quantitative image reconstruction technology based on deep learning to reconstruct T1, T2 and T2 * quantitative images. According to the method, movie imaging for heart function examination and T1 quantitative imaging, T2 quantitative imaging and T2 * quantitative imaging for myocardial tissue characterization are completed in one-time scanning.

The invention features methods for the treatment of a cardiovascular disease using a polypeptide containing an extracellular ActRII variant, such as an ActRIIA variant, ActRIIB variant, or ActRII chimera. The polypeptide may include an extracellular ActRII variant fused to an Fc domain monomer. Treatment of a cardiovascular disease with a polypeptide described herein may reduce fibrosis, reduce inflammation, reduce cardiac remodeling, improve cardiac function, improve ventricular function, or slow or inhibit disease progression, which may reduce or delay the need for coronary revascularization, heart valve repair or replacement, implantation of a cardioverter-defibrillator, cardiac resynchronization therapy, a ventricular assist device, or a heart transplant.

The invention discloses a myocardial amyloidosis quantitative analysis method based on SPECT imaging and related equipment, and relates to the field of wisdom medical device.The method comprises the steps that firstly, three-dimensional SPECT original data of N time phases of a target patient in the cardiac cycle are collected, a mu graph is generated based on low-dose CT for registration and attenuation correction, and a dynamic image is reconstructed; and then an MR structure sequence under synchronous electrocardio gating is obtained, and SPECT and MR space standardization and partial volume effect correction processing are completed. And unifying the cardiac cycle image form through affine and nonlinear transformation, and generating a high-quality enhanced SPECT image. Finally, radioactive counting information is extracted on the basis of three-dimensional segmentation, multiple myocardial quantitative indexes are calculated, comprehensive analysis of myocardial functions is achieved in combination with left ventricular functional parameters, and accurate image support is provided for non-invasive diagnosis and curative effect evaluation of myocardial amyloidosis.

The present invention discloses a method for drawing and interpreting a real-time three-dimensional volume loop of the left atrium and ventricle, and belongs to the field of cardiac ultrasound. The method of the present invention comprises the following steps: S1, image retention: using a Philips echocardiogram instrument with a Philips Heart Model mode and equipped with an X5-1 probe to use the Heart Model mode to retain images of at least 6 cardiac cycles on the apical four-chamber section; S2, software analysis: analyzing the retained images to obtain a real-time synchronized three-dimensional volume curve of the left atrium and left ventricle; S3, point drawing: the corresponding left atrium and left ventricle volumes taken at different times on the three-dimensional volume curve in the software are drawn with the left ventricle volume as the X-axis and the left atrium volume as the Y-axis; the present invention can easily judge the left atrium and ventricle function and the left atrium and ventricle relationship through the real-time synchronized left atrium and ventricle volume curve, can identify abnormal heart function that cannot be identified by conventional echocardiogram, and avoid fragmented analysis of the left atrium and ventricle function; high repeatability and no harm to the human body.

The invention provides a novel model for diagnosis and prognosis of sepsis cardiomyopathy and a construction method thereof. The element TMAD in the new model has the advantages that the element TMAD does not depend on the high cardiac hypersonic image quality and is easy and convenient to operate, no radiation or side effect exists, and the ventricular function can be accurately and rapidly evaluated; compared with LVEF sensitivity, the method has the advantages that left ventricular systolic function changes can be reflected earlier, measurement repeatability is quite good, and the method is particularly suitable for patients with poor cardiac ultrasound image quality; as a relatively new ventricular strain measurement technology, the ventricular strain can be obtained through further analysis by system software, the operation and software image analysis steps are simple, the ventricular strain can be skillfully applied through certain clinical training, the environment is not polluted, the health of an operator is not influenced, and the patient acceptability is relatively high; the method has high feasibility in diagnosis of sepsis cardiomyopathy.

The invention features methods for the treatment of a cardiovascular disease using a polypeptide containing an extracellular ActRII variant, such as an ActRIIA variant, ActRIIB variant, or ActRII chimera. The polypeptide may include an extracellular ActRII variant fused to an Fc domain monomer. Treatment of a cardiovascular disease with a polypeptide described herein may reduce fibrosis, reduce inflammation, reduce cardiac remodeling, improve cardiac function, improve ventricular function, or slow or inhibit disease progression, which may reduce or delay the need for coronary revascularization, heart valve repair or replacement, implantation of a cardioverter-defibrillator, cardiac resynchronization therapy, a ventricular assist device, or a heart transplant.

Systems and methods to obtain high-quality apical 4-chamber-long-axis (A4CLAX) views of the mouse heart. The pathological progression of heart function following transverse aortic constriction (TAC) surgery is monitored using both a long-axis biplane (LAX-BP) and the conventional PSAX-M mode assays. A clear visualization of both mitral and tricuspid valve leaflets in A4CLAX view images enabled detecting dysfunctions such as valve regurgitation and desynchronized opening due lower chamber contractile desynchronies. Additionally, A4CLAX echocardiography facilitated the characterization of right ventricle (RV) dysfunction in mice, including RV dilation, higher diastolic filling pressures, and early characterization of decreased RV free wall longitudinal strain caused by pulmonary hypertension secondary to TAC procedure. Furthermore, A4CLAX imaging expands upon our capabilities to study left atrial and appendage function. The A4CLAX methodology allows significantly more clinically comparable echocardiographic analyses in murine heart, including a LAX-BP assay that provides CMR-comparable accuracy to evaluate the LV volumes.

The application discloses a method, system, device, medium and product for evaluating right ventricular function, and relates to the technical field of medical image processing and ultrasonic diagnosis. The method comprises the following steps: acquiring a sequence of multiple two-dimensional ultrasonic images of a right ventricle of a heart and spatial pose information of the sequence, and generating point cloud data; identifying an end-diastolic frame, an end-systolic frame and an anatomical structure point, and acquiring sparse point cloud data of the anatomical structure point; constructing a three-dimensional grid model of the end-diastolic frame and the end-systolic frame; determining multiple tracking points of a tricuspid annulus and acquiring a three-dimensional coordinate trajectory; calculating longitudinal displacement, area change rate and peak time dispersion based on the trajectory, and completing function evaluation. The application overcomes the limitations of angle dependence and point substitution of traditional TAPSE technology, realizes comprehensive evaluation of right ventricular function from three dimensions of longitudinal displacement, area change rate and systolic synchrony, and improves the accuracy and clinical value of evaluation.

The application provides use of a trisaccharide compound with a core structure of GlcN(1→4)IdoA(1→4)GlcNS in preparation of a drug for treating or preventing pulmonary arterial hypertension, which can effectively improve right ventricular hypertrophy, right ventricular function damage and hemodynamic parameters of an animal model of the pulmonary arterial hypertension, delay or improve excessive proliferation of arterial endothelial cells and smooth muscle cells in the pulmonary arterial hypertension, treat vascular remodeling and vascular muscularization of a pulmonary arterial hypertension patient, and has a good protective effect on a heart in the pulmonary arterial hypertension.

The utility model belongs to the technical field of pulmonary vessel guiding catheters, and particularly relates to a pulmonary vessel guiding catheter which can be used for right heart function examination. The technology comprises a guiding catheter, and a floating catheter is arranged in the guiding catheter in a penetrating mode. According to the technical scheme, the functions of an existing right heart floating catheter and an existing pulmonary vessel guiding catheter are organically combined, and the function effects of the original right heart floating catheter and the original pulmonary vessel guiding catheter are achieved through one set of technical scheme. Specifically, a guiding catheter in the prior art is adopted, and physical characteristics such as proper flexibility and strength are utilized to adapt to various bends and steers in a blood vessel; a floating catheter in the prior art is adopted to realize pulmonary vessel intervention operation; the floating catheter is arranged in the guiding catheter, so that the guiding catheter can be used for right heart function examination and pulmonary vessel intervention operation, and clinical diversified requirements are met.

The invention discloses a method, a system, equipment, a medium and a product for evaluating a right ventricular function, and relates to the technical field of medical image processing and ultrasonic diagnosis. The method comprises the following steps: acquiring a multi-frame two-dimensional ultrasonic image sequence of a right ventricle of a heart and spatial pose information of the multi-frame two-dimensional ultrasonic image sequence, and generating point cloud data; identifying the last diastole frame, the last systole frame and the anatomical structure point, and obtaining sparse point cloud data of the anatomical structure point; constructing a three-dimensional grid model of the last diastole frame and the last systole frame; determining a plurality of tracking points of the tricuspid valve ring and acquiring a three-dimensional coordinate trajectory; and calculating the longitudinal displacement, the area change rate and the peak arrival time dispersion based on the trajectory to complete the function evaluation. According to the method, the limitation that a traditional TAPSE technology depends on a point instead of a surface is overcome, comprehensive evaluation of the right ventricular function from the three dimensions of longitudinal displacement, the area change rate and contraction synchronism is achieved, and the accuracy and clinical value of evaluation are improved.

The invention discloses a device for detecting and evaluating a right heart function after a heart transplantation operation. Relates to the technical field of medical instruments. The supporting assembly is arranged on the movable base in a rotatable mode; the cardiac ultrasound equipment is arranged on the supporting assembly; and the blood pressure and hemodynamics detection equipment is also arranged on the supporting assembly, and the blood pressure and hemodynamics detection equipment is arranged opposite to the cardiac ultrasound equipment. According to the detection device, ultrasonic detection can be conducted on the right heart function after the heart transplantation operation, meanwhile, pulmonary artery pressure and hemodynamic detection can be conducted, whether the structure and the function of the heart are abnormal or not is known by observing the right heart state after the transplantation operation, the heart function is closely detected after the operation, and the prognosis of a patient is remarkably improved.

Disclosed herein, in some aspects, are systems and methods for treating hypertrophic cardiomyopathy (HCM) in a subject. In some embodiments, the systems and methods described herein comprise monitoring a cardiac performance and optionally detecting an abnormality of said cardiac performance, in some cases after an initial HCM treatment is administered. In some cases, the initial HCM treatment includes administration of a myosin inhibitor, and / or septal myectomy. In some embodiments, said cardiac performance correlates with a right ventricular function and / or a pulmonary arterial pressure. In some embodiments, systems and methods described herein comprise identifying a therapy for a subject so as to help reduce the risk of de-performance teriorating a cardiac performance. In some cases, identifying the therapy includes predicting an effectiveness of a therapy with respect to a cardiac performance. In some embodiments, a recommendation is provided for adjusting a therapy based on an observed effect on a cardiac performance.

This invention belongs to the field of traditional Chinese medicine, specifically relating to a traditional Chinese medicine composition for preventing and treating cardiotoxicity induced by doxorubicin and its application; the traditional Chinese medicine composition for preventing and treating cardiotoxicity induced by doxorubicin is composed of ginseng and salvia miltiorrhiza; this invention finds that the traditional Chinese medicine composition can promote the survival rate of doxorubicin-induced cardiomyocyte H9c2, reduce doxorubicin-induced apoptosis of cardiomyocyte H9c2, reduce doxorubicin-induced oxidative stress damage and cardiac damage, improve left ventricular function, and improve doxorubicin-induced cardiotoxicity, which is of great significance for the prevention and treatment of azithromycin-induced cardiotoxicity.

Various methods and compositions for treating single ventricle heart disease (SVHD) patients, including patients who have undergone Fontan surgery and who have Fontan circulation (Fontan patient), to improve exercise performance, single ventricular performance, cardiac output and myocardial performance index (MPI) in the SVHD patients, including the Fontan patients, using udenafil compositions.In one exemplary embodiment, the methods of the present invention include administering an effective amount of udenafil or a pharmaceutically acceptable salt thereof to a SVHD patient, including a Fontan, to improve the ventricular performance of the SVHD patient's, including the Fontan patient's, single functioning ventricle.In another exemplary embodiment, the methods of the present invention include administering an effective amount of udenafil or a pharmaceutically acceptable salt thereof to a SVHD patient, including a Fontan patient, to improve the SVHD patient's, including the Fontan patient's, MPI.In still another exemplary embodiment, the methods of the present invention include administering an effective amount of udenafil or a pharmaceutically acceptable salt thereof to a SVHD patient, including a Fontan patient, to improve the SVHD patient's, including the Fontan patient's, cardiac output.In yet another exemplary embodiment, the methods of the present invention include administering an effective amount of udenafil or a pharmaceutically acceptable salt thereof to a SVHD patient, including a Fontan patient, who is about 6 years of age or older, to improve at least one or more or all of the following in the SVHD patient, including the Fontan patient: (a) ventricular performance of the SVHD patient's, including a Fontan patient's, single functioning ventricle as measured by MPI; (b) exercise capacity as measured by oxygen consumption at anaerobic threshold (VAT); (c) exercise capacity as measured by oxygen consumption at maximal effort or max VO2; (d) work rate at VAT; (e) VE / VCO2 at VAT; diastolic blood pressure at rest; and (g) oxygen saturation (%) at rest.

The invention provides application of a chalcone compound in preparation of a medicine for treating or preventing pulmonary arterial hypertension. The medicine can effectively improve hypertrophy of a right ventricle of a pulmonary arterial hypertension animal model, functional damage of the right ventricle and hemodynamic parameters.